Search

DexCom Inc

Lezárt

SzektorEgészségügy

79.14 0.71

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

77.98

Maximum

79.81

Fő mutatók

By Trading Economics

Bevétel

50M

249M

Értékesítés

117M

1.3B

P/E

Szektor átlag

31.179

50.373

Egy részvényre jutó nyereség

0.7

Profit margin

19.039

Munkavállalók

11,000

EBITDA

52M

389M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+22.68% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. okt. 29.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.3B

30B

Előző nyitás

78.43

Előző zárás

79.14

DexCom Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. okt. 27. 19:36 UTC

Dexcom Inc is trading modestly higher, having fluctuated earlier in the session before pulling back from its mid-morning peak.

2026. okt. 22. 20:02 UTC

Dexcom Inc shares are declining, reversing a trend of higher daily closes observed since Wednesday's close.

2026. okt. 21. 20:01 UTC

Dexcom Inc shares fell sharply, marking a downward shift and diverging from the recent trend of higher daily closes.

2026. okt. 20. 20:08 UTC

Dexcom Inc shares are declining, pulling back from an earlier session high, and have dropped slightly since Monday's close.

2026. okt. 19. 20:07 UTC

Dexcom Inc shares are declining, showing a slight drop since Friday's close amid routine market movement within the midpoint of its one-month trading range.

2026. okt. 16. 23:06 UTC

Dexcom Inc shares are advancing modestly in after-market trading following Friday's close, currently positioned within the middle of its one-month trading range.

2026. okt. 15. 20:02 UTC

Social Media
News

Dexcom Inc shares advanced sharply after the CONNECT study showed significant A1C reduction and improved glucose target range for users of the Dexcom G7.

2026. okt. 14. 23:01 UTC

News

Dexcom's stock advanced in after-market trading following the CONNECT study publication, showing the G7 lowers A1C levels by an average of 1.6% for Type 2 diabetes patients.

2026. okt. 13. 19:53 UTC

Dexcom Inc shares are declining amid significant downward movement in the Health Care Equipment sub-sector, currently positioned near the lower end of its one-month range.

2026. okt. 12. 19:16 UTC

News

BTIG reiterates Buy rating on Dexcom Inc and raises price target to $96, according to a report released earlier today.

2026. okt. 8. 19:15 UTC

Dexcom Inc shares are trading roughly flat, with a slight cumulative return since Wednesday's close, amid broader market weakness.

2026. okt. 7. 23:55 UTC

Dexcom Inc's shares have declined in after-market trading, settling lower after an early high and remaining below their 20-day moving average.

2026. okt. 6. 20:00 UTC

Dexcom Inc shares fell sharply, breaking a trend of higher daily closes established since Monday, amid a decline contrasting recent upward momentum.

2026. okt. 5. 20:06 UTC

Dexcom Inc. is trading higher today, reflecting a generally positive market environment following an early dip and steady rise in broader market activity.

2026. okt. 2. 20:07 UTC

Dexcom Inc's shares are declining, pulling back from earlier gains and trading below their 20-day moving average amid Friday's session.

2026. szept. 30. 20:07 UTC

Dexcom Inc shares fell lower Wednesday, following a modest decline from Tuesday's close, despite briefly peaking earlier in the session.

2026. szept. 25. 20:07 UTC

Dexcom Inc shares fell sharply, continuing a downward trajectory and closing lower compared to Thursday, remaining below its 20-day moving average.

2026. szept. 23. 20:07 UTC

Dexcom Inc shares fell sharply after an earlier rise, reflecting a decline compared to Tuesday's close amid broader market weakness.

2026. szept. 22. 20:07 UTC

Dexcom Inc is seeing a modest gain, reflecting stability near the upper end of its one-month range and above its 20-day moving average.

2026. szept. 18. 20:07 UTC

News

Dexcom Inc shares are advancing as Truist Securities raised its price target to $102 and TD Cowen reiterated its Buy rating with a $95 target.

2026. szept. 17. 19:26 UTC

News

Dexcom's stock is higher as Truist Securities raises its price target to $102.00 from $93.00, maintaining a Buy rating.

2026. szept. 16. 20:10 UTC

Dexcom Inc is trading higher, reaching a peak in late morning and settling above Tuesday's close, marking three consecutive daily gains.

2026. szept. 15. 20:01 UTC

Dexcom Inc shares are trading higher amid broader market concerns following a significant decline in the NY Empire State Manufacturing Index.

2026. szept. 10. 19:36 UTC

Dexcom Inc shares are higher in Thursday's session, recovering from an initial dip. The stock remains below its 20-day moving average. No specific news identified.

2026. szept. 9. 22:11 UTC

Dexcom Inc shares are higher in after-market trading, reflecting a positive shift since Wednesday's close, despite recent lower closes and no specific news.

2026. szept. 8. 20:01 UTC

Dexcom Inc. shares are lower today, trading significantly below their 20-day moving average amid speculation of a potential Federal Reserve interest rate hike.

2026. aug. 28. 20:08 UTC

Dexcom Inc shares are higher today, aligning with a broader market increase. The asset is trading above its 20-day moving average.

2026. aug. 26. 19:16 UTC

Dexcom Inc's shares are higher today, reaching their peak around 14:50 ET. The stock remains above its 20-day moving average.

2026. aug. 25. 20:07 UTC

Dexcom Inc. shares are lower today amid broader market weakness. The stock remains above its 20-day moving average despite recent declines since Monday's close.

2026. aug. 21. 19:36 UTC

Social Media

Dexcom Inc shares are higher as $1.6 million in call options signals bullish investor sentiment. The stock has recovered from earlier session lows.

Társak összehasonlítása

Árváltozás

DexCom Inc Előrejelzés

Célár

By TipRanks

22.68% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 96.389 USD  22.68%

Magas 115 USD

Alacsony 82 USD

20 Wall Street elemző 12 hónapos célárain alapulva a(z)DexCom Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

20 ratings

19

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat